MALDI ESI peptide characterisation: selecting mass spectrometry methods

Matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI) represent the two dominant soft-ionisation techniques in peptide mass spectrometry. Both enable molecular-weight determination and structural analysis of synthetic peptides without fragmentation, yet they differ fundamentally in sample presentation, ionisation physics and practical workflow. Selecting between MALDI and ESI depends on the peptide's chemical properties, the analytical question at hand, and the instrumentation available in your laboratory.

MALDI ESI peptide characterisation has become routine in research settings because both methods produce singly or multiply charged ions from intact peptide molecules, yielding accurate mass data across the 500–5000 Da range typical of short-chain research peptides. However, their complementary strengths mean that many laboratories now employ both techniques within a single characterisation protocol.

MALDI relies on a solid-state sample preparation workflow. The peptide is co-crystallised with a small-molecule organic matrix (typically α-cyano-4-hydroxycinnamic acid or sinapinic acid) on a steel target plate. A UV or near-infrared laser then ablates the matrix, transferring internal energy to the peptide and generating primarily singly charged ions ([M+H]⁺ or [M+Na]⁺). This simplicity of ionisation — one peptide, one charge state — makes MALDI spectra straightforward to interpret.

The solid-state format also confers practical advantages. Samples are stable on the target plate for days or weeks, permitting batch analysis and archiving. MALDI tolerates salts and buffers reasonably well because the crystalline matrix isolates the analyte from the salt matrix; this makes MALDI particularly suitable for peptides recovered from aqueous synthetic or purification workflows. Time-of-flight (ToF) detection is the standard coupling, delivering sub-ppm mass accuracy when calibrated with peptide standards.

Electrospray ionisation presents the peptide as a fine aerosol of charged droplets, generated by applying a high electric field (typically 3–4 kV) at the tip of a capillary carrying a flowing solution. Solvent evaporation and Coulomb fission progressively reduce droplet size, eventually releasing naked peptide ions into the gas phase. Unlike MALDI, ESI routinely produces multiply charged ions ([M+2H]²⁺, [M+3H]³⁺ etc.), a phenomenon especially pronounced for basic peptides rich in lysine and arginine residues.

This multi-charge feature enables ESI to analyse peptides well beyond the nominal mass range of ToF detectors. A 10 kDa peptide becomes a singly charged 10,000 m/z ion in MALDI, but a 5,000 m/z doubly charged ion in ESI — both sit comfortably within modern quadrupole or orbitrap detector windows. ESI also couples naturally to liquid chromatography (LC-ESI-MS or LC-MS), permitting real-time analysis of peptide mixtures, including purity assessment and separation of isobaric species during liquid-phase chromatography.

MALDI sample preparation is minimal but requires technique. The peptide solution (typically 1–10 pmol/µL in water or dilute organic solvent) is mixed 1:1 with matrix solution, spotted onto the target plate, and allowed to air-dry. The resulting co-crystal must be homogeneous; uneven crystallisation produces spatial heterogeneity in ion current across the spot. Automated spotting systems mitigate this variability. Total hands-on time is short, and consumable cost is negligible.

ESI sample preparation is less operator-dependent but demands continuous solvent flow. The peptide is dissolved in volatile solvent (water, methanol, acetonitrile, typically with formic acid or acetic acid as an ionisation promoter), loaded into a syringe or autosampler vial, and fed through a capillary at flow rates of 1–10 µL/min. The instrument must equilibrate before data acquisition begins. If hyphenated to chromatography, the entire separation chromatogram generates mass data simultaneously; if infused directly (nanoESI), a few microlitres of solution yields several minutes of stable signal.

MALDI excels at rapid survey analysis of multiple discrete samples. A researcher can load a 384-well or 1536-well formatted target plate, programme the instrument to acquire one or two spectra per well, and obtain molecular weights for dozens of peptides in a single unattended run. MALDI is also the de facto standard for bottom-up proteomics (peptide fingerprinting) because the post-source decay (PSD) fragmentations can be acquired without tandem MS hardware.

ESI shines in hyphenated LC-MS workflows, where retention time and chromatographic purity become integral to structure assessment. For peptides prone to hydrophobic aggregation or precipitation, ESI's aqueous-compatible solvents and on-line separation prevent sample loss and decomposition. ESI-MS/MS (tandem mass spectrometry with quadrupole or orbitrap analysers) generates peptide sequence data through collision-induced fragmentation, a capability routinely exploited in peptide mapping and quantitative proteomics. ESI is also superior for peptides bearing labile modifications (phosphorylation, glycosylation) because the soft-ionisation conditions and brief residence time in the ion source minimise unwanted rearrangements.

Choose MALDI if you require rapid, high-throughput screening of synthetic peptides, if your peptides are small (< 5 kDa) and charge-resistant, if sample solubility is poor, or if you need archival stability on a target plate. MALDI also remains the pragmatic choice if your laboratory has invested in a MALDI-ToF instrument but lacks LC-MS capability. Its tolerance of salt and buffer permits direct analysis of crude synthetic products or purification fractions without prior desalting.

Choose ESI if you need quantitative accuracy, if your peptides are > 5 kDa or likely to adopt multiple charge states, if you require real-time purity assessment during chromatography, or if you plan tandem-MS sequencing or modification mapping. ESI is also preferable for peptides containing labile post-translational modifications, because the lower kinetic energy of ESI-generated ions and the absence of a matrix background reduce decomposition risk.

Many well-resourced research laboratories employ both methods in parallel. MALDI provides rapid confirmation of crude synthetic products, whilst ESI-LC offers purity validation and sequence confirmation before a peptide proceeds to higher-value downstream assays. This combined approach maximises confidence in peptide identity and structure.

MALDI troubleshooting often centres on matrix choice and crystallisation homogeneity. Hydrophilic peptides work well with α-cyano-4-hydroxycinnamic acid; lipophilic or acidic peptides may require sinapinic acid or alternative matrices. Poor signal frequently indicates uneven crystal formation, remedied by varying the matrix:sample ratio, spotting volume, or air-drying conditions. Salt contamination rarely causes complete signal loss in MALDI, but can suppress ionisation; if suspect, dilute the sample 10-fold or perform a brief desalting step on a C18 micropipette tip.

ESI troubleshooting typically involves solvent composition and sample concentration. Low or unstable signal suggests either too-dilute peptide (raise concentration to 0.1–1 µM) or insufficient ionisation promoter (ensure formic acid or acetic acid is present at 0.1–1% v/v). Multiply charged ion distributions skewed toward high charge states indicate excessive acidity; reduce acid concentration or increase pH slightly. For nanoESI infusion, blockage of the capillary is the commonest failure; replace the needle, re-centre it optically, and restart with fresh solvent. Coupling to HPLC demands that the mobile phase remain volatile; non-volatile buffers or very high salt concentrations suppress ESI signal catastrophically.